The NHS Innovation and Technology Payment (ITP) programme went live on 1 April 2018. Four innovations will be fast-tracked into use through the programme, supported by the AHSN Network. One of these is SecurAcath.
Innovation type: device
A device to secure catheters without requiring sutures or adhesives.
Patients may experience several complications when peripherally inserted central catheters (PICC) are moved or dislodged at the insertion site. During weekly routine dressing changes, the adhesive dressing are removed, leaving the catheter unsecured and at risk of movement and migration, which can lead to these adverse patient impacts:
- Interruptions or delays in therapy
- Increased length of hospital stay or extended treatment plan
- Increased readmissions to hospital
- Repeat procedures
- Damaged vessels from catheter movement, pistoning or recatheterisation
- Medical adhesive related skin injury (MARSI)
- Complications including catheter occlusion, phlebitis, thrombosis and infection.
The cost of replacing an adhesive securement on a weekly basis is around £5. Replacement costs of catheters can range from £150 to £1,500. Additional costs to consider are extending treatments and complication management.
Compared to adhesive securement devices, SecurAcath provides continuous securement from catheter placement and never needs to be changed.
The concept for SecurAcath came from an Interventional Radiologist at the University of Minnesota. He encountered patients with catheter securement issues on a daily basis and identified unmet needs for a robust catheter securement device that could overcome the challenges that adhesive devices and sutures caused.
SecurAcath does not require sutures or adhesives. It secures at the insertion site using small, flexible securement feet placed in the subcutaneous tissue below the dermis. This allows for improved site cleaning, less catheter manipulation and eliminates risk of accidental dislodgement or migration during routine dressing changes. Because SecurAcath lasts the life of the line, this lowers the total cost of patient care by dramatically reducing the complications related to routine adhesive securement changes and sutures.
Modelling shows a savings of £9-95 per patient compared to the Statlock adhesive securement device. Cost savings result from shorter maintenance times and less need for device replacement when using SecurAcath. Annual savings across the NHS in England from using SecurAcath are estimated to be a minimum of £4.2 million based on data reviewed by the NICE Advisory Committee. NICE estimated that 128,000 patients were eligible for the SecurAcath each year in England.
NICE concluded that the case for adopting SecurAcath is supported by the evidence. Using SecurAcath avoids the need for securement device replacement and is associated with a low incidence of catheter- associated complications, such as migration, occlusion, phlebitis, thrombosis and infection.
Find out more
Scott Baker, Director, Market & Clinical Development
07468 493406 or firstname.lastname@example.org
Aquilant Medical (SecurAcath UK distributor partner) – SecurAcath enquiries page: